Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.51 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.46 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8087274 | 0.98 | LPL (0.54) | LPLLIPGPPARAPPARGCYP4F2 | |
| SCHEMBL8102302 | 0.98 | LPL (0.54) | LPLLIPGPPARAPPARGCYP4F2 | |
| SCHEMBL8094372 | 0.98 | LPL (0.54) | LPLLIPGPPARAPPARGCYP4F2 | |
| SCHEMBL8087128 | 0.95 | CYP4F2 (0.51) | LPLLIPGPPARAPPARGCYP4F2 | |
| SCHEMBL3892580 | 0.88 | KAT6A (0.50) | CYP4F2CYP4A11MAP1LC3BMAP1LC3A | |
| Hexane SCHEMBL5195484 | 0.86 | SMN1; SMN2 (0.55) | THRB | |
| SCHEMBL443913 | 0.85 | RARB (0.58) | LPLLIPGPPARAPPARG | |
| SCHEMBL8095894 | 0.85 | LPL (0.54) | LPLLIPGPPARAPPARGCYP4F2 | |
| SCHEMBL755940 | 0.85 | LPL (0.54) | LPLLIPGPPARAPPARGCYP4F2 | |
| SCHEMBL289254 | 0.83 | RARB (0.59) | LPLLIPGPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422231-B2 | Method for inhibiting Trypanosoma cruzi | HOWARD UNIVERSITY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150073177-A1 | METHOD FOR INHIBITING TRYPANOSOMA CRUZI | HOWARD UNIVERRSITY (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140336187-A1 | METHODS FOR TREATING LEISHMANIASIS | HOWARD UNIVERSITY | 2014-11-13 | — | — | US | disclosed |
| WO-2013074930-A1 | METHODS FOR TREATING LEISHMANIASIS | HOWARD UNIVERSITY (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013016661-A1 | METHOD FOR INHIBITING TRYPANSOMA CRUZI | HOWARD UNIVERSITY (US) | 2013-01-31 | — | — | WO | disclosed |
| EP-0708077-B1 | Diamino compounds and methods for preparing them | CHISSO CORP (JP) | 2000-12-27 | — | — | EP | disclosed |
| US-5663440-A | Diamino compounds and methods for preparing them | CHISSO CORPORATION (JP) | 1997-09-02 | — | — | US | disclosed |
| EP-0708077-A1 | Diamino compounds and methods for preparing them | CHISSO CORPORATION (JP) | 1996-04-24 | — | — | EP | disclosed |
| US-5290950-A | Containing chromophore and ionophore groups, complexing metals, analysis of body fluids | WAYNE STATE UNIVERSITY (US) | 1994-03-01 | — | — | US | disclosed |
| US-5096832-A | Complexing, spectrophotometry | WAYNE STATE UNIVERSITY (US) | 1992-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336187-A1 | METHODS FOR TREATING LEISHMANIASIS | LSS, CYP51A1, NQO1 | LPL 1161/4885LIPG 1476/4885PPARA 2105/4885 |
| US-20150073177-A1 | METHOD FOR INHIBITING TRYPANOSOMA CRUZI | PCNA, NQO1, NQO2 | LPL 3389/4885LIPG 3434/4885PPARA 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.